Progress of breast cancer with low expression of human epidermal growth factor receptor 2

VernacularTitle:人表皮生长因子受体2低表达乳腺癌的研究进展
Author: Xiangdong WU ¹ ; Donghong XU
Author Information

1. 保定市第一中心医院乳腺外科，保定　071000
Keywords: Breast neoplasms; Human epidermal growth factor receptor 2; Targeted therapy; Antibody drug conjugates
From: Cancer Research and Clinic 2024;36(8):630-633
CountryChina
Language:Chinese
Abstract: Human epidermal growth factor receptor 2 (HER2) is an important therapeutic target for breast cancer in recent years. The emergence of targeted drugs represented as trastuzumab has drastically improved the prognosis of HER2-positive breast cancer patients. Antibody-drug conjugates (ADC) such as trastuzumab deruxtecan (T-DXd) have shown the obvious therapeutic efficacies in breast cancer with HER2 low expression recently, which has become a research hotpot. With the deepening of the research, new views of the detection of HER2 and the molecular subtypes of breast cancer are proposed, besides, the concept of ultra-low HER2 expression is also proposed by some scholars. Several studies have explored the application of ADC and new treatments in HER2 low expression breast cancer. This paper reviews the definition, the detection and determination, clinicopathologic characteristics and treatment progress of breast cancer with HER2 low expression.